Intraperitoneal Paclitaxel

Phase 3Small molecule

Intraperitoneal Paclitaxel is one of 24 small molecule programs targeting Malignant Peritoneal Mesothelioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant Peritoneal MesotheliomaActive, not recruiting

Gastric CancerActive, not recruiting

Gastric Cancer Peritoneal MetastasesRecruiting

Malignant Peritoneal MesotheliomaPhase 1/Phase 2

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Gastric Cancer Peritoneal MetastasesPhase 3

Recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

S-1 Plus Oxaliplatin

FFudan University

Phase 3

2 2

Capecitabine+oxaliplatin

Roche

Phase 3

1 3

Intraperitoneal Paclitaxel

EECOG-ACRIN Cancer Research Group

Phase 3

1 4

Gemzar

Johnson & Johnson

Preclinical

—5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Induction Phase1

Genmab

Preclinical

1 9

Glutamine

Sanofi

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2/3Recruiting

Gastric Cancer

NCT07001748

Q1 2031

Phase 3Recruiting

Gastric Cancer Peritoneal Metastases

NCT07304271

Clinical

Trials by Indication[1]

Malignant Peritoneal Mesothelioma1 trial

Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma

Completed·EErasmus Medical Center·Phase 1/2·NCT05449366·7 enrolled

Gastric Cancer1 trial

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Recruiting·EECOG-ACRIN Cancer Research Group·Phase 2/3·NCT07001748·148 enrolled

Gastric Cancer Peritoneal Metastases1 trial

Randomised Phase III Trial of First Line Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastases - IPa-Gastric

Recruiting·MMagnus Nilsson·Phase 3·NCT07304271·262 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Intraperitoneal Paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intraperitoneal Paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intraperitoneal Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ECOG-ACRIN Cancer Research Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EECOG-ACRIN Cancer Research Group

Intraperitoneal Paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Q1 2031

Trials by Indication[1]

Malignant Peritoneal Mesothelioma1 trial

Gastric Cancer1 trial

Gastric Cancer Peritoneal Metastases1 trial

References

Drug Info

Quick Facts

Related News